Joy Goldstein

Title(s)Affiliate
SchoolKeck School of Medicine of Usc
Address4640 West Sunset Blvd
Off Campus
Los Angeles CA 90027
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. CYP2C8 Is a Novel Target of Peroxisome Proliferator-Activated Receptor α in Human Liver. Mol Pharmacol. 2016 Jan; 89(1):154-64. Makia NL, Goldstein JA. PMID: 26467040; PMCID: PMC4702104.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    2. Epigenetic modification of histone 3 lysine 27: mediator subunit MED25 is required for the dissociation of polycomb repressive complex 2 from the promoter of cytochrome P450 2C9. J Biol Chem. 2015 Jan 23; 290(4):2264-78. Englert NA, Luo G, Goldstein JA, Surapureddi S. PMID: 25391650; PMCID: PMC4303677.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    3. The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping. Pharmacogenet Genomics. 2014 Aug; 24(8):381-6. Langaee TY, Zhu HJ, Wang X, El Rouby N, Markowitz JS, Goldstein JA, Johnson JA. PMID: 24945780; PMCID: PMC4090277.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    4. Med25 is required for estrogen receptor alpha (ERα)-mediated regulation of human CYP2C9 expression. Biochem Pharmacol. 2014 Aug 15; 90(4):425-31. Shi Z, Yang W, Goldstein JA, Zhang SY. PMID: 24960263; PMCID: PMC4292888.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    5. Regulation of human CYP2C9 expression by electrophilic stress involves activator protein 1 activation and DNA looping. Mol Pharmacol. 2014 Aug; 86(2):125-37. Makia NL, Surapureddi S, Monostory K, Prough RA, Goldstein JA. PMID: 24830941; PMCID: PMC4127925.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    6. RBCK1, an E3 ubiquitin ligase, interacts with and ubiquinates the human pregnane X receptor. Drug Metab Dispos. 2013 Feb; 41(2):398-405. Rana R, Coulter S, Kinyamu H, Goldstein JA. PMID: 23160820; PMCID: PMC3558864.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    7. Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients. Transplantation. 2012 Nov 15; 94(9):971-7. Sam WJ, Chamberlain CE, Lee SJ, Goldstein JA, Hale DA, Mannon RB, Kirk AD, Hon YY. PMID: 23073467; PMCID: PMC3491093.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    8. Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Br J Clin Pharmacol. 2012 Sep; 74(3):445-55. Joy MS, La M, Wang J, Bridges AS, Hu Y, Hogan SL, Frye RF, Blaisdell J, Goldstein JA, Dooley MA, Brouwer KL, Falk RJ. PMID: 22380717; PMCID: PMC3477346.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    9. Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver. Mol Pharmacol. 2012 Sep; 82(3):529-40. Zhang SY, Surapureddi S, Coulter S, Ferguson SS, Goldstein JA. PMID: 22723340; PMCID: PMC3422698.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    10. Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities. Drug Metab Pharmacokinet. 2012; 27(6):663-7. Lee SJ, Goldstein JA. PMID: 22785258; PMCID: PMC3602955.
      View in: PubMed   Mentions: 5     Fields:    Translation:Cells
    11. P2X7 receptor-NADPH oxidase axis mediates protein radical formation and Kupffer cell activation in carbon tetrachloride-mediated steatohepatitis in obese mice. Free Radic Biol Med. 2012 May 01; 52(9):1666-79. Chatterjee S, Rana R, Corbett J, Kadiiska MB, Goldstein J, Mason RP. PMID: 22343416; PMCID: PMC3341527.
      View in: PubMed   Mentions: 36     Fields:    Translation:AnimalsCells
    12. Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients. Transplantation. 2011 Dec 27; 92(12):1342-7. Sam WJ, Chamberlain CE, Lee SJ, Goldstein JA, Hale DA, Mannon RB, Kirk AD, Hon YY. PMID: 22094953; PMCID: PMC3237821.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    13. Liganded pregnane X receptor represses the human sulfotransferase SULT1E1 promoter through disrupting its chromatin structure. Nucleic Acids Res. 2011 Oct; 39(19):8392-403. Kodama S, Hosseinpour F, Goldstein JA, Negishi M. PMID: 21764778; PMCID: PMC3201858.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    14. NCOA6 differentially regulates the expression of the CYP2C9 and CYP3A4 genes. Pharmacol Res. 2011 May; 63(5):405-13. Surapureddi S, Rana R, Goldstein JA. PMID: 21292004; PMCID: PMC3082001.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    15. Med25 is required for RNA polymerase II recruitment to specific promoters, thus regulating xenobiotic and lipid metabolism in human liver. Mol Cell Biol. 2011 Feb; 31(3):466-81. Rana R, Surapureddi S, Kam W, Ferguson S, Goldstein JA. PMID: 21135126; PMCID: PMC3028616.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    16. The nuclear receptors constitutive active/androstane receptor and pregnane x receptor activate the Cyp2c55 gene in mouse liver. Drug Metab Dispos. 2010 Jul; 38(7):1177-82. Konno Y, Kamino H, Moore R, Lih F, Tomer KB, Zeldin DC, Goldstein JA, Negishi M. PMID: 20371638; PMCID: PMC2908984.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    17. Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes. Drug Metab Dispos. 2010 Apr; 38(4):591-9. Rana R, Chen Y, Ferguson SS, Kissling GE, Surapureddi S, Goldstein JA. PMID: 20086032; PMCID: PMC2845933.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    18. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur J Clin Pharmacol. 2009 Sep; 65(9):947-53. Joy MS, Dornbrook-Lavender K, Blaisdell J, Hilliard T, Boyette T, Hu Y, Hogan SL, Candiani C, Falk RJ, Goldstein JA. PMID: 19669737; PMCID: PMC2901912.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    19. The transcriptional regulation of the human CYP2C genes. Curr Drug Metab. 2009 Jul; 10(6):567-78. Chen Y, Goldstein JA. PMID: 19702536; PMCID: PMC2808111.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    20. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009 Apr; 20(4):912-21. Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT, Allon M. PMID: 19225037; PMCID: PMC2663833.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    21. Identification of human CYP2C8 as a retinoid-related orphan nuclear receptor target gene. J Pharmacol Exp Ther. 2009 Apr; 329(1):192-201. Chen Y, Coulter S, Jetten AM, Goldstein JA. PMID: 19164466; PMCID: PMC2670598.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    22. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics. 2008 Oct; 9(10):1445-58. Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N. PMID: 18855533; PMCID: PMC2586955.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    23. Nuclear receptor coactivator 6 mediates the synergistic activation of human cytochrome P-450 2C9 by the constitutive androstane receptor and hepatic nuclear factor-4alpha. Mol Pharmacol. 2008 Sep; 74(3):913-23. Surapureddi S, Rana R, Reddy JK, Goldstein JA. PMID: 18552123; PMCID: PMC3815599.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    24. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics. 2008 May; 9(5):511-26. Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT. PMID: 18466099; PMCID: PMC2757655.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    25. Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol. 2008 Mar; 73(3):1029-36. van Waterschoot RA, van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, Goldstein JA, Zeldin DC, Beijnen JH, Schinkel AH. PMID: 18156313; PMCID: PMC2391091.
      View in: PubMed   Mentions: 31     Fields:    Translation:AnimalsCells
    26. The discovery of new coding alleles of human CYP26A1 that are potentially defective in the metabolism of all-trans retinoic acid and their assessment in a recombinant cDNA expression system. Pharmacogenet Genomics. 2007 Mar; 17(3):169-80. Lee SJ, Perera L, Coulter SJ, Mohrenweiser HW, Jetten A, Goldstein JA. PMID: 17460545; PMCID: PMC2393551.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    27. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos. 2007 Apr; 35(4):682-8. Delozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, Murphy E, Steenbergen C, Zeldin DC, Goldstein JA. PMID: 17220242; PMCID: PMC2747652.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    28. A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system. Drug Metab Dispos. 2007 Jan; 35(1):67-71. Lee SJ, van der Heiden IP, Goldstein JA, van Schaik RH. PMID: 17035598; PMCID: PMC3302370.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    29. Phenytoin induction of the cyp2c37 gene is mediated by the constitutive androstane receptor. Drug Metab Dispos. 2006 Dec; 34(12):2003-10. Jackson JP, Ferguson SS, Negishi M, Goldstein JA. PMID: 16936065; PMCID: PMC1676033.
      View in: PubMed   Mentions: 21     Fields:    Translation:Animals
    30. Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450. J Pharmacol Exp Ther. 2006 Oct; 319(1):488-96. Vyas PM, Roychowdhury S, Khan FD, Prisinzano TE, Lamba J, Schuetz EG, Blaisdell J, Goldstein JA, Munson KL, Hines RN, Svensson CK. PMID: 16857728.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    31. Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition. J Clin Pharmacol. 2006 May; 46(5):515-26. Lee SJ, Jusko WJ, Salaita CG, Calis KA, Jann MW, Spratlin VE, Goldstein JA, Hon YY. PMID: 16638735; PMCID: PMC4182867.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    32. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec; 315(3):1085-90. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA. PMID: 16099926.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    33. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol. 2005 Sep; 68(3):747-57. Ferguson SS, Chen Y, LeCluyse EL, Negishi M, Goldstein JA. PMID: 15933212.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    34. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics. 2005 Jun; 6(4):357-71. Lee SJ, Goldstein JA. PMID: 16004554.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    35. The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter. J Pharmacol Exp Ther. 2005 Sep; 314(3):1125-33. Chen Y, Kissling G, Negishi M, Goldstein JA. PMID: 15919766.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    36. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther. 2005 Apr; 313(1):302-9. Lee SJ, Bell DA, Coulter SJ, Ghanayem B, Goldstein JA. PMID: 15634941.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    37. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics. 2005 Jan; 15(1):7-13. King LM, Gainer JV, David GL, Dai D, Goldstein JA, Brown NJ, Zeldin DC. PMID: 15864120.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    38. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug; 14(8):527-37. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA. PMID: 15284535.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    39. The constitutive active/androstane receptor regulates phenytoin induction of Cyp2c29. Mol Pharmacol. 2004 Jun; 65(6):1397-404. Jackson JP, Ferguson SS, Moore R, Negishi M, Goldstein JA. PMID: 15155833.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    40. Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities. Mol Pharmacol. 2004 May; 65(5):1148-58. Wang H, Zhao Y, Bradbury JA, Graves JP, Foley J, Blaisdell JA, Goldstein JA, Zeldin DC. PMID: 15102943.
      View in: PubMed   Mentions: 37     Fields:    Translation:AnimalsCells
    41. CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J Pharmacol Exp Ther. 2004 Sep; 310(3):845-54. DeLozier TC, Tsao CC, Coulter SJ, Foley J, Bradbury JA, Zeldin DC, Goldstein JA. PMID: 15084647.
      View in: PubMed   Mentions: 41     Fields:    Translation:AnimalsCells
    42. CYP2C9 genetic polymorphisms and warfarin. Clin Appl Thromb Hemost. 2004 Apr; 10(2):149-54. Redman AR, Dickmann LJ, Kidd RS, Goldstein JA, Ritchie DM, Hon YY. PMID: 15094935.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    43. Mouse liver CYP2C39 is a novel retinoic acid 4-hydroxylase. Its down-regulation offers a molecular basis for liver retinoid accumulation and fibrosis in aryl hydrocarbon receptor-null mice. J Biol Chem. 2004 Jan 30; 279(5):3434-8. Andreola F, Hayhurst GP, Luo G, Ferguson SS, Gonzalez FJ, Goldstein JA, De Luca LM. PMID: 14623888.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    44. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther. 2004 Feb; 308(2):495-501. Chen Y, Ferguson SS, Negishi M, Goldstein JA. PMID: 14600250.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    45. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol. 2003 Aug; 64(2):316-24. Chen Y, Ferguson SS, Negishi M, Goldstein JA. PMID: 12869636.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    46. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics. 2003 Aug; 13(8):461-72. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, Mohrenweiser HW, Goldstein JA. PMID: 12893984.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    47. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy. 2003 Jun; 23(6):720-5. Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. PMID: 12820813.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    48. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur J Clin Pharmacol. 2003 Apr; 58(12):791-4. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. PMID: 12698304.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    49. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol. 2003 Jan; 43(1):84-91. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. PMID: 12520632.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    50. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics. 2002 Dec; 12(9):703-11. Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, Xi T, Ghanayem B, Goldstein JA. PMID: 12464799.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    51. Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. Clin Pharmacol Ther. 2002 Sep; 72(3):238-46. Fischer TL, Pieper JA, Graff DW, Rodgers JE, Fischer JD, Parnell KJ, Goldstein JA, Greenwood R, Patterson JH. PMID: 12235444.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    52. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002 Apr; 12(3):251-63. Lee CR, Goldstein JA, Pieper JA. PMID: 11927841.
      View in: PubMed   Mentions: 187     Fields:    Translation:Humans
    53. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Pharmacogenetics. 2002 Apr; 12(3):221-5. Tassaneeyakul W, Tawalee A, Tassaneeyakul W, Kukongviriyapan V, Blaisdell J, Goldstein JA, Gaysornsiri D. PMID: 11927837.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    54. In vitro human metabolism and interactions of repellent N,N-diethyl-m-toluamide. Drug Metab Dispos. 2002 Mar; 30(3):289-94. Usmani KA, Rose RL, Goldstein JA, Taylor WG, Brimfield AA, Hodgson E. PMID: 11854147.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    Joy's Networks
    Concepts (307)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (1)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.